EHA 2019 – presentations and articles

During 2019 European Hematology Association (EHA) Congress, Oncopeptides presented updated interim data from the ongoing phase 1/2 ANCHOR study, data from its phase 1/2 O-12-M1 study and updated interim...

ASCO 2019 – presentations and articles

During 2019 ASCO General Meeting (American Society of Clinical Oncology), Oncopeptides presented new data from phase 1/2 O-12-M1 trial evaluating melflufen in RRMM. These data was presented by Professor...

Post EHA – webcast regarding data update

Oncopeptides hosted a webcast on Monday, 17 June at 09:00 (CET) to review and update presentations from European Hematology Association (EHA) meeting. It was presented by CEO Jakob Lindberg and members...

REDEYE Growth Day – Presentation

Oncopeptides CFO Anders Martin-Löf held a presentation at the REDEYE Growth Day, 10 June 2019. The Presentation was recorded and can be showed at the link below. Below is also a link to an EFN interview ...

Webcast regarding operational update

Oncopeptides held an operational update on Tuesday, May 21, 2019, at. 10:00 (CET). It was presented by CEO Jakob Lindberg and members of the Oncopeptides management team. The webcast was recorded. See...

EHA Abstracts 2019

Upcoming presentations at EHA The HORIZON data will be presented as an oral presentation by Professor Paul G. Richardson, in the session “Novel strategies in multiple myeloma” on June 16 at 08.45 (CET) in ...

ASCO Abstract 2019

Oncopeptides has a poster presentation of data from its Phase 1/2 O-12-M1 study at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4 in Chicago. The study e...

Webcast regarding clinical program update

Oncopeptides held an webcast April 24, 2019, where CEO Jakob Lindberg provided new guidance on the patient recruitment in the OCEAN study and a clinical program update. The webcast was recorded. See the...

AACR 2019 – Posters

At the AACR (American Association for Cancer Research) Annual Meeting 2019 Oncopeptides presented two Posters for the studies ANCHOR and HORIZON. AACR Annual Meeting 2019, March 29 - Apr 3, in Atlanta,...

Webcast Year-End Report 2018

The Year-end Report for 2018 and an operational update was presented by CEO Jakob Lindberg and members of Oncopeptides management team, February 22, 2019 at 14:00 (CET). The conference was streamed via...

ASH 2018 – presentations and articles

During the American Hematology Meeting (ASH), Oncopeptides presented data from two ongoing studies, ANCHOR and HORIZON. These presentations as well as publications in the media are presented below. The...

ASH Abstracs 2018

Oncopeptides to present updated data from the two ongoing trials ANCHOR and HORIZON in patients with RRMM at ASH in December 2018. The abstract data cut for ANCHOR was July 18th and for HORIZON, May 10th....

ASH summary Webcast

Oncopeptides had a press conference on December 13. The conference was recorded. Click here to view the Webcast.
Back to top